Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
The findings could help to develop microbiota-based strategies to advance immunothery treatments for melanoma.
New research reveals that ocean-derived genes are common in the human microbiota, highlighting the interplay between diet and adaptation of human gut microbes.
Researchers have found that β-carotene modifies the abundance of certain gut microbes and improves the intestinal dysfunctions
Researchers have found that combining a probiotic product with immunotherapy may boost anti-tumor responses in people with advanced kidney cancer.
Researchers have found that Lactobacilli could be used to treat common acne lesions, reducing the need for topical antibiotics.
Researchers have found that some gut microbes may be connected to depression, thus highlighting that the intricate relationship between humans and their microbiota could have important health implications.
Researchers have now found that the interactions between existing gut commensals sets the odds for whether new microbes are acquired.
Researchers have found that testosterone-degrading enzymes expressed by gut microbes are associated with depressive symptoms.
Researchers have found that microbes in the gut of ground squirrels recycle a waste product into building blocks to make proteins, helping the animals to survive a long winter without…
Akkermansia can be used as a biomarker to identify who is likely to respond to treatment with immune checkpoint inhibitors. A new study published in Nature Medicine claims
